News for BFRA Stock

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs Biofrontera AG announces mediation results Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021 Biofrontera AG announces initiation of clinical studies Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021 Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp Biofrontera reports preliminary approximate revenues for the month of September 2021 Biofrontera reports preliminary revenue for the month of August 2021 Biofrontera reports financial results for the six months ended June 30, 2021 Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021 Biofrontera reports preliminary revenue for the month of July 2021 Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland Biofrontera Inc. seeks IPO in the USA Biofrontera reports preliminary revenue for the month of June 2021 Biofrontera provides update on clinical developments Biofrontera reports preliminary revenue for the month of May 2021 Biofrontera reports Q1 2021 financial results Biofrontera reports preliminary revenue for the month of April 2021 Biofrontera AG: First quarter conference call to be held on May 12, 2021 Biofrontera reports results for the 2020 financial year Biofrontera announces preliminary revenue for Q1 2021 Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million Biofrontera submits study report of pharmacokinetics study to FDA Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court Biofrontera reports preliminary unaudited sales revenue for the third quarter of 2020 Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court Biofrontera AG plans mediation to resolve (legal) disputes Biofrontera report results for the first six months of 2020 Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021 Result of the subscription of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021 Biofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021 Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds Biofrontera reports preliminary unaudited sales revenue for the first six months of 2020 Biofrontera reports Q1 2020 financial results Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results Supervisory Board of Biofrontera AG renews Management Board appointment Results of the 2020 Annual General Meeting of Biofrontera AG Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court